fda warning letter semaglutide october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The Food and Drug Administration
Description
What makes GLP-1 users unique is the speed and magnitude of their results, which can sometimes magnify visible changes in the skin
Related Blog Katherine, a weight loss coach at here since 2016, uses her Certified Medical Assistant expertise to guide clients to wellness success

To address these uncertainties, longer-term studies with larger and more globally diverse participant groups are necessary

( PMID:39355484;PMCID:PMC11444311 )
